Last reviewed · How we verify
IMU-838
At a glance
| Generic name | IMU-838 |
|---|---|
| Also known as | vidofludimus calcium, Vidofludimus calcium, IM90838, Intervention Arm |
| Sponsor | Immunic AG |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (PHASE3)
- Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (PHASE3)
- A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19) (PHASE2, PHASE3)
- Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis (PHASE2)
- MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) (PHASE2)
- Phase 2 Dose-finding IMU-838 for Ulcerative Colitis (PHASE2)
- IMU-838 and Oseltamivir in the Treatment of COVID-19 (PHASE2)
- Vidofludimus Calcium for Primary Sclerosing Cholangitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMU-838 CI brief — competitive landscape report
- IMU-838 updates RSS · CI watch RSS
- Immunic AG portfolio CI